Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
In this first study of inhaled apomorphine in Parkinson's disease patients, the primary
objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing
patients during 'off' periods. Safety, tolerability and pharmacokinetics of inhaled
apomorphine will be assessed during the study.